{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:07:57Z","timestamp":1794506877739,"version":"4.9.1"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>The goal of this study was to investigate the use of transient-evoked otoacoustic emissions (TEOAEs) and middle ear absorbance measurements to monitor auditory function in patients with cystic fibrosis (CF) receiving ototoxic medications. TEOAEs were elicited with a chirp stimulus using an extended bandwidth (0.71 to 8\u2009kHz) to measure cochlear function at higher frequencies than traditional TEOAEs. Absorbance over a wide bandwidth (0.25 to 8\u2009kHz) provides information on middle ear function. The combination of these time-efficient measurements has the potential to identify early signs of ototoxic hearing loss.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>A longitudinal study design was used to monitor the hearing of 91 patients with CF (median age = 25 years; age range = 15 to 63 years) who received known ototoxic medications (e.g., tobramycin) to prevent or treat bacterial lung infections. Results were compared to 37 normally hearing young adults (median age = 32.5 years; age range = 18 to 65 years) without a history of CF or similar treatments. Clinical testing included 226-Hz tympanometry, pure-tone air-conduction threshold testing from 0.25 to 16\u2009kHz and bone conduction from 0.25 to 4\u2009kHz. Experimental testing included wideband absorbance at ambient and tympanometric peak pressure and TEOAEs in three stimulus conditions: at ambient pressure and at tympanometric peak pressure using a chirp stimulus with constant incident pressure level across frequency and at ambient pressure using a chirp stimulus with constant absorbed sound power across frequency.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>At the initial visit, behavioral audiometric results indicated that 76 of the 157 ears (48%) from patients with CF had normal hearing, whereas 81 of these ears (52%) had sensorineural hearing loss for at least one frequency. Seven ears from four patients had a confirmed behavioral change in hearing threshold for \u22653 visits during study participation. Receiver operating characteristic curve analyses demonstrated that all three TEOAE conditions were useful for distinguishing CF ears with normal hearing from ears with sensorineural hearing loss, with an area under the receiver operating characteristic curve values ranging from 0.78 to 0.92 across methods for frequency bands from 2.8 to 8\u2009kHz. Case studies are presented to illustrate the relationship between changes in audiometric thresholds, TEOAEs, and absorbance across study visits. Absorbance measures permitted identification of potential middle ear dysfunction at 5.7 kHz in an ear that exhibited a temporary hearing loss.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The joint use of TEOAEs and absorbance has the potential to explain fluctuations in audiometric thresholds due to changes in cochlear function, middle ear function, or both. These findings are encouraging for the joint use of TEOAE and wideband absorbance objective tests for monitoring ototoxicity, particularly, in patients who may be too ill for behavioral hearing tests. Additional longitudinal studies are needed in a larger number of CF patients receiving ototoxic drugs to further evaluate the clinical utility of these measures in an ototoxic monitoring program.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aud.0000000000000464","type":"journal-article","created":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T15:18:17Z","timestamp":1500045497000},"page":"69-84","source":"Crossref","is-referenced-by-count":14,"title":["Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients"],"prefix":"10.1097","volume":"39","author":[{"given":"Angela C.","family":"Garinis","sequence":"first","affiliation":[{"name":"Pulmonary & Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas H.","family":"Keefe","sequence":"additional","affiliation":[{"name":"Pulmonary & Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa L.","family":"Hunter","sequence":"additional","affiliation":[{"name":"Pulmonary & Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis F.","family":"Fitzpatrick","sequence":"additional","affiliation":[{"name":"Pulmonary & Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Putterman","sequence":"additional","affiliation":[{"name":"Pulmonary & Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garnett P.","family":"McMillan","sequence":"additional","affiliation":[{"name":"Pulmonary & Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Gold","sequence":"additional","affiliation":[{"name":"Pulmonary & Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Patrick","family":"Feeney","sequence":"additional","affiliation":[{"name":"Pulmonary & Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230726","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jcf.2014.07.009","article-title":"High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.","volume":"14","author":"Al-Malky","year":"2015","journal-title":"J Cyst Fibros"},{"key":"R2-20230726","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/14992027.2010.524253","article-title":"Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions.","volume":"50","author":"Al-Malky","year":"2011","journal-title":"Int J Audiol"},{"issue":"Suppl 12","key":"R6-20230726","first-page":"11","article-title":"Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy.","volume":"36","year":"1994","journal-title":"ASHA"},{"key":"R8-20230726","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/14992020309101328","article-title":"Immediate and short-term reliability of distortion-product otoacoustic emissions.","volume":"42","author":"Beattie","year":"2003","journal-title":"Int J Audiol"},{"key":"R10-20230726","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1121\/1.3279831","article-title":"High-frequency transient evoked otoacoustic emissions acquisition with auditory canal compensated clicks using swept-tone analysis.","volume":"127","author":"Bennett","year":"2010a","journal-title":"J Acoust Soc Am"},{"key":"R11-20230726","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1121\/1.3467769","article-title":"Swept-tone transient-evoked otoacoustic emissions.","volume":"128","author":"Bennett","year":"2010b","journal-title":"J Acoust Soc Am"},{"key":"R12-20230726","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2165\/00003495-198019060-00002","article-title":"Drug-induced ototoxicity.","volume":"19","author":"Brummett","year":"1980","journal-title":"Drugs"},{"key":"R13-20230726","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.otohns.2009.03.020","article-title":"Sensorineural hearing loss in patients with cystic fibrosis.","volume":"141","author":"Cheng","year":"2009","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R15-20230726","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"R16-20230726","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1121\/1.3473693","article-title":"Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.","volume":"128","author":"Dille","year":"2010","journal-title":"J Acoust Soc Am"},{"key":"R17-20230726","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00003446-199904000-00006","article-title":"Predicting audiometric status from distortion product otoacoustic emissions using multivariate analyses.","volume":"20","author":"Dorn","year":"1999","journal-title":"Ear Hear"},{"key":"R18-20230726","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-0040-1715734","article-title":"Comparison of ABR stimuli for the early detection of ototoxicity: conventional clicks compared with high frequency clicks and single frequency tonebursts.","volume":"14","author":"Fausti","year":"2003","journal-title":"J Am Acad Audiol"},{"key":"R19-20230726","first-page":"397","article-title":"Early detection of ototoxicity using high-frequency, tone-burst-evoked auditory brainstem responses.","volume":"3","author":"Fausti","year":"1992","journal-title":"J Am Acad Audiol"},{"key":"R20-20230726","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00003446-199912000-00005","article-title":"An individualized, sensitive frequency range for early detection of ototoxicity.","volume":"20","author":"Fausti","year":"1999","journal-title":"Ear Hear"},{"key":"R21-20230726","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archotol.1993.01880180081015","article-title":"High-frequency monitoring for early detection of cisplatin ototoxicity.","volume":"119","author":"Fausti","year":"1993","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R22-20230726","first-page":"105","article-title":"Reliability of evoked responses to high-frequency (8-14\u2009kHz) tone bursts.","volume":"2","author":"Fausti","year":"1991","journal-title":"J Am Acad Audiol"},{"key":"R25-20230726","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1097\/AUD.0000000000000399","article-title":"Normative wideband reflectance, equivalent admittance at the tympanic membrane, and acoustic stapedius reflex threshold in adults.","volume":"38","author":"Feeney","year":"2017","journal-title":"Ear Hear"},{"key":"R28-20230726","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00003446-199212000-00008","article-title":"Test\/retest reliability of distortion-product and transiently evoked otoacoustic emissions.","volume":"13","author":"Franklin","year":"1992","journal-title":"Ear Hear"},{"key":"R29-20230726","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jcf.2017.01.006","article-title":"The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.","volume":"16","author":"Garinis","year":"2017","journal-title":"J Cyst Fibros"},{"key":"R30-20230726","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1121\/1.3056566","article-title":"High-frequency click-evoked otoacoustic emissions and behavioral thresholds in humans.","volume":"125","author":"Goodman","year":"2009","journal-title":"J Acoust Soc Am"},{"issue":"4 Pt 1","key":"R31-20230726","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1121\/1.406691","article-title":"Otoacoustic emissions from normal-hearing and hearing-impaired subjects: distortion product responses.","volume":"93","author":"Gorga","year":"1993a","journal-title":"J Acoust Soc Am"},{"key":"R32-20230726","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1121\/1.407348","article-title":"A comparison of transient-evoked and distortion product otoacoustic emissions in normal-hearing and hearing-impaired subjects.","volume":"94","author":"Gorga","year":"1993b","journal-title":"J Acoust Soc Am"},{"key":"R33-20230726","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1121\/1.410227","article-title":"Towards understanding the limits of distortion product otoacoustic emission measurements.","volume":"96","author":"Gorga","year":"1994","journal-title":"J Acoust Soc Am"},{"key":"R34-20230726","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00003446-199712000-00003","article-title":"From laboratory to clinic: a large scale study of distortion product otoacoustic emissions in ears with normal hearing and ears with hearing loss.","volume":"18","author":"Gorga","year":"1997","journal-title":"Ear Hear"},{"issue":"2 Pt 1","key":"R35-20230726","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1121\/1.416208","article-title":"The use of cumulative distributions to determine critical values and levels of confidence for clinical distortion product otoacoustic emission measurements.","volume":"100","author":"Gorga","year":"1996","journal-title":"J Acoust Soc Am"},{"key":"R36-20230726","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00003446-199902000-00007","article-title":"Characteristics of transient evoked otoacoustic emissions in normal-hearing and hearing-impaired children.","volume":"20","author":"Harrison","year":"1999","journal-title":"Ear Hear"},{"key":"R39-20230726","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1121\/1.4807505","article-title":"Measuring stimulus-frequency otoacoustic emissions using swept tones.","volume":"134","author":"Kalluri","year":"2013","journal-title":"J Acoust Soc Am"},{"key":"R40-20230726","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1121\/1.4757734","article-title":"Moments of click-evoked otoacoustic emissions in human ears: group delay and spread, instantaneous frequency and bandwidth.","volume":"132","author":"Keefe","year":"2012","journal-title":"J Acoust Soc Am"},{"key":"R42-20230726","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1121\/1.407347","article-title":"Ear-canal impedance and reflection coefficient in human infants and adults.","volume":"94","author":"Keefe","year":"1993","journal-title":"J Acoust Soc Am"},{"key":"R43-20230726","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1121\/1.4962532","article-title":"Comparisons of transient evoked otoacoustic emissions using chirp and click stimuli.","volume":"140","author":"Keefe","year":"2016","journal-title":"J Acoust Soc Am"},{"key":"R44-20230726","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1121\/1.4974146","article-title":"Comparing otoacoustic emissions evoked by chirp transients with constant absorbed sound power and constant incident pressure magnitude.","volume":"141","author":"Keefe","year":"2017","journal-title":"J Acoust Soc Am"},{"key":"R45-20230726","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1121\/1.3514527","article-title":"Detecting high-frequency hearing loss with click-evoked otoacoustic emissions.","volume":"129","author":"Keefe","year":"2011","journal-title":"J Acoust Soc Am"},{"key":"R46-20230726","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1121\/1.4936946","article-title":"Procedures for ambient-pressure and tympanometric tests of aural acoustic reflectance and admittance in human infants and adults.","volume":"138","author":"Keefe","year":"2015","journal-title":"J Acoust Soc Am"},{"key":"R47-20230726","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3109\/14992027.2012.721936","article-title":"Wideband aural acoustic absorbance predicts conductive hearing loss in children.","volume":"51","author":"Keefe","year":"2012","journal-title":"Int J Audiol"},{"key":"R49-20230726","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00003446-199004000-00004","article-title":"A guide to the effective use of otoacoustic emissions.","volume":"11","author":"Kemp","year":"1990","journal-title":"Ear Hear"},{"key":"R50-20230726","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2006.07.9723","article-title":"Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.","volume":"25","author":"Knight","year":"2007","journal-title":"J Clin Oncol"},{"key":"R51-20230726","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/019459988108900626","article-title":"Ototoxicity of kanamycin sulfate and the barriers in the inner ear.","volume":"89","author":"Komune","year":"1981","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R52-20230726","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0196-0709(83)80003-9","article-title":"Ototoxicity of cis-dichlorodiammine platinum (II) in guinea pigs.","volume":"4","author":"Konishi","year":"1983","journal-title":"Am J Otolaryngol"},{"key":"R53-20230726","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1682\/JRRD.2013.04.0092","article-title":"Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA).","volume":"51","author":"Konrad-Martin","year":"2014","journal-title":"J Rehabil Res Dev"},{"issue":"Suppl 1","key":"R54-20230726","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.3109\/14992027.2011.635713","article-title":"Multivariate DPOAE metrics for identifying changes in hearing: perspectives from ototoxicity monitoring.","volume":"51","author":"Konrad-Martin","year":"2012","journal-title":"Int J Audiol"},{"key":"R55-20230726","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1121\/1.3001712","article-title":"Wideband absorbance tympanometry using pressure sweeps: system development and results on adults with normal hearing.","volume":"124","author":"Liu","year":"2008","journal-title":"J Acoust Soc Am"},{"issue":"1","key":"R56-20230726","first-page":"65","article-title":"Distortion-produce otoacoustic emissions in rabbit: I. Altered susceptibility to repeated pure-tone exposures.","volume":"70","author":"Lonsbury-Martin","year":"1993","journal-title":"Hear Res"},{"key":"R57-20230726","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00003446-199706000-00005","article-title":"Effect of negative middle-ear pressure on transient-evoked otoacoustic emissions.","volume":"18","author":"Marshall","year":"1997","journal-title":"Ear Hear"},{"key":"R59-20230726","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijporl.2010.01.021","article-title":"Hearing loss in cystic fibrosis.","volume":"74","author":"Martins","year":"2010","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"R60-20230726","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1128\/AAC.45.9.2502-2509.2001","article-title":"Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.","volume":"45","author":"Mulheran","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R61-20230726","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/AAC.00995-05","article-title":"Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.","volume":"50","author":"Mulheran","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"4 Pt 1","key":"R62-20230726","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1121\/1.403695","article-title":"Effect of ear-canal air pressure on evoked otoacoustic emissions.","volume":"91","author":"Naeve","year":"1992","journal-title":"J Acoust Soc Am"},{"key":"R63-20230726","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/00016488209128887","article-title":"Application of loop diuretics for treatment of sensorineural hearing impairment. Experimental and clinical study.","volume":"94","author":"Nakai","year":"1982","journal-title":"Acta Otolaryngol"},{"key":"R65-20230726","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1445-5994.2001.00010.x","article-title":"Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia.","volume":"31","author":"Phillips","year":"2001","journal-title":"Intern Med J"},{"key":"R66-20230726","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1121\/1.405715","article-title":"Analysis of transient-evoked otoacoustic emissions in normal-hearing and hearing-impaired ears.","volume":"93","author":"Prieve","year":"1993","journal-title":"J Acoust Soc Am"},{"key":"R67-20230726","doi-asserted-by":"crossref","DOI":"10.1097\/AUD.0000000000000425","article-title":"Using wideband transient-evoked otoacoustic emissions to assess sensorineural hearing loss","author":"Putterman","year":"2017","journal-title":"Ear Hear"},{"key":"R68-20230726","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/hn.1999.v121.a101567","article-title":"Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Third place\u2013Resident Clinical Science Award 1998.","volume":"121","author":"Ress","year":"1999","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R69-20230726","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/00206099309072943","article-title":"Repeatability of distortion product otoacoustic emissions in normally hearing humans.","volume":"32","author":"Roede","year":"1993","journal-title":"Audiology"},{"key":"R70-20230726","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/00016480903015150","article-title":"No hearing loss after repeated courses of tobramycin in cystic fibrosis patients.","volume":"130","author":"Scheenstra","year":"2010","journal-title":"Acta Otolaryngol"},{"issue":"2 Pt1","key":"R78-20230726","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1121\/1.426948","article-title":"Evoked otoaocustic emissions arise by two fundamentally different mechanisms: a taxonomy for mammalian OAEs.","volume":"105","author":"Shera","year":"1999","journal-title":"J Acoust Soc Am"},{"key":"R79-20230726","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1121\/1.405717","article-title":"Noninvasive measurement of the cochlear traveling-wave ratio.","volume":"93","author":"Shera","year":"1993","journal-title":"J Acoust Soc Am"},{"key":"R73-20230726","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/AUD.0b013e3182280326","article-title":"Ear canal pressure variations versus negative middle ear pressure: comparison using distortion product otoacoustic emission measurement in humans.","volume":"33","author":"Sun","year":"2012","journal-title":"Ear Hear"},{"key":"R74-20230726","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1164\/rccm.200109-012CC","article-title":"Aminoglycoside prescribing and surveillance in cystic fibrosis.","volume":"167","author":"Tan","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R75-20230726","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00003446-199312000-00005","article-title":"The effect of middle ear pressure on transient evoked otoacoustic emissions.","volume":"14","author":"Trine","year":"1993","journal-title":"Ear Hear"},{"key":"R76-20230726","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ppul.20985","article-title":"A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis.","volume":"44","author":"Van Meter","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"R77-20230726","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/GIM.0b013e318156dd07","article-title":"Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes.","volume":"9","author":"Veenstra","year":"2007","journal-title":"Genet Med"},{"key":"R80-20230726","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1121\/1.413320","article-title":"The origin of periodicity in the spectrum of evoked otoacoustic emissions.","volume":"98","author":"Zweig","year":"1995","journal-title":"J Acoust Soc Am"}],"container-title":["Ear &amp; Hearing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003446-201801000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T08:08:37Z","timestamp":1690358917000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003446-201801000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/aud.0000000000000464","relation":{},"ISSN":["0196-0202"],"issn-type":[{"value":"0196-0202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}